Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556611 | 0.89 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL910409 | 0.85 | NPC1 (0.55) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL443143 | 0.82 | AHR (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9210543 | 0.77 | CYP1A2 (0.39) | NPC1MAPTKIF11CYP1A2CYP11B1 | |
| SCHEMBL615272 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3357269 | 0.77 | CRBN (0.39) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3352150 | 0.75 | CYP11B1 (0.31) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL19639065 | 0.74 | CRBN (0.41) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1450276 | 0.74 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1744832 | 0.72 | PDE3B (0.46) | PDE3BPDE3ACYP11B1CYP11B2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-09-21 | — | — | US | claimed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | claimed |
| EP-4185588-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2023-05-31 | — | — | EP | claimed |
| CN-116134035-A | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2023-05-16 | — | — | CN | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | claimed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | claimed |
| US-20210246137-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-08-12 | — | — | US | claimed |
| EP-0701560-A1 | BICYCLIC ETHER DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1996-03-20 | — | — | EP | claimed |
| US-5478842-A | Antiinflammatory agents, antiallergens, drugs for treatment of diseases mediated by leukotrienes | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | claimed |
| US-5478843-A | Administering as inhibitors of the enzyme 5-lipoxygenase | ZENECA LIMITED (GB) | 1995-12-26 | — | — | US | claimed |
| WO-1995030668-A1 | CYCLIC ETHER DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | ZENECA LIMITED (GB) | 1995-11-16 | — | — | WO | claimed |
| WO-1995004055-A1 | THIAZOLE DERIVATIVES AS LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1995-02-09 | — | — | WO | claimed |
| EP-0636624-A1 | Thiazole derivatives as lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1995-02-01 | — | — | EP | claimed |
| WO-1994029297-A1 | 2-OXO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-12-22 | — | — | WO | claimed |
| WO-1994027999-A1 | BICYCLIC ETHER DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-12-08 | — | — | WO | claimed |
| WO-1994025453-A1 | 4-ARYL-4-HYDROXY-TETRAHYDROPYRANS AND 3-ARYL-3-HYDROXY-TETRAHYDROFURANS AS 5-LIPOXYGENASE INHIBITORS | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | claimed |
| EP-0623614-A1 | 4-Aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LIMITED (GB) | 1994-11-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | NPC1 1812/4885MAPK13 3355/4885MAPK12 3084/4885 |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | NPC1 1416/4885MAPK13 2275/4885MAPK12 2330/4885 |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | NPC1 801/4885MAPK13 98/4885MAPK12 398/4885 |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | SERPINC1, F11, TFPI2 | NPC1 2222/4885MAPK13 585/4885MAPK12 1787/4885 |
| US-20210246137-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, HSP90B1, CEP170 | NPC1 801/4885MAPK13 98/4885MAPK12 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.